[1] Alberg A J, Samet J M. Epidemiology of lung cancer[J]. Chest, 2003,123(Suppl 1):21-49.[2] Molina J R, Yang P, Cassivi S D, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship[J]. Mayo Clin Proc, 2008,83(5):584-594.[3] Toh C K, Gao F, Lim W T, et al. Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity[J]. J Clin Oncol, 2006,24(15):2245-2251.[4] Hull J, Ackerman H, Isles K, et al. Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus[J]. Am J Hum Genet, 2001,69(2):413-419.[5] Baggiolini M, Walz A, Kunkel S L. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils[J]. J Clin Invest, 1989,84(4):1045-1049.[6] Rollins B J. Chemokines[J]. Blood, 1997,90(3):909-928.[7] Du H, Bay B H, Mahendran R, et al. Endogenous expression of interleukin-8, interleukin-10 in nasopharyngeal carcinoma cells, the effect of photodynamic therapy[J]. Int J Mol Med, 2002,10(1):73-76.[8] Heinzmann A, Ahlert I, Kurz T, et al. Association study suggests opposite effects of polymorphisms within IL8 on bron-chial asthma, respiratory syncytial virus bronchiolitis[J]. J Allergy Clin Immunol, 2004,114(3):671-676.[9] van Aken B E, Reitsma P H, Rosendaal F R. Interleukin 8, venous thrombosis: evidence for a role of inflammation in thrombosis[J]. Br J Haematol, 2002,116(1):173-177.[10] Koch A E, Polverini P J, Kunkel S L, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis[J]. Science, 1992,258(5089):1798-1801.[11] Kitadai Y, Haruma K, Mukaida N, et al. Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8[J]. Clin Cancer Res, 2000,6(7):2735-2740.[12] Bendre M S, Gaddy-Kurten D, Mon-Foote T, et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo[J]. Cancer Res, 2002,62(19):5571-5579.[13] Li A, Dubey S, Varney M L, et al. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metallopro-teinases production and regulated angiogenesis[J]. J Immunol, 2003,170(6):3369-3376.[14] Cochran W G. The combination of estimates from different experiments[J]. Biometrics, 1954,10(1):101-129.[15] Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease[J]. J Natl Cancer Inst, 1959,22(4):719-748.[16] DerSimonian R, Laird N. Meta-analysis in clinical trials[J]. Control Clin Trials, 1986,7(3):177-188.[17] Tobias A. Assessing the influence of a single study in the meta-analysis estimate[J]. Stata Tech Bull, 1999,8(47):15-17.[18] Egger M, Davey Smith G, Schneider M, et al. Bias in metaanalysis detected by a simple, graphical test[J]. BMJ, 1997,315(7109):629-634.[19] Bhat I A, Pandith A A, Bhat B A, et al. Lack of association of a common polymorphism in the 3'-UTR of interleukin 8 with non small cell lung cancer in Kashmir[J]. Asian Pac J Cancer Prev, 2013,14(7):4403-4408.[20] Rafrafi A, Chahed B, Kaabachi S, et al. Association of IL-8 gene polymorphisms with non small cell lung cancer in Tunisia: a case control study[J]. Hum Immunol, 2013,74(10):1368-1374.[21] Lee K M, Shen M, Chapman R S, et al. Polymorphisms in immunoregulatory genes, smoky coal exposure and lung cancer risk in Xuan Wei, China[J]. Carcinogenesis, 2007,28(7):1437-1441.[22] Vogel U, Christensen J, Wallin H, et al. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a pro-spective study[J]. Mutat Res, 2008,639(1-2):89-100.[23] Campa D, Hung R J, Mates D, et al. Lack of association between-251T/A polymorphism of IL8, lung cancer risk[J]. Cancer Epidemiol Biomarkers Prev, 2005,14(10):2457-2458.[24] Campa D, Zienolddiny S, Maggini V, et al. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer[J]. Carcinogenesis, 2004,25(2):229-235.[25] Hull J, Rowlands K, Lockhart E, et al. Haplotype mapping of the bronchiolitis susceptibility locus near IL8[J]. Hum Genet, 2004,114(3):272-279.[26] Cheng D, Hao Y, Zhou W, et al. Positive association between Interleukin-8-251A>T polymorphism and susceptibility to gastric carcinogenesis: a meta-analysis[J]. Cancer Cell Int, 2013,13(1):100.[27] Wang Z, Liu Y, Yang L, et al. The polymorphism interleukin-8-251A/T is associated with a significantly increased risk of cancers from a Meta-analysis[J]. Tumour Biol, 2014,35(7):7115-7123.[28] Hirschhorn J N, Lohmueller K, Byrne E, et al. A comprehensive review of genetic association studies[J]. Genet Med, 2002,4(2):45-61.[29] Canedo P, Castanheira-Vale A J, Lunet N, et al. The interleukin-8-251*T/*A polymorphism is not associated with risk for gastric carcinoma development in a Portuguese population[J]. Eur J Cancer Prev, 2008,17(1):28-32.[30] Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families[J]. Thorax, 2000,55(12):1023-1027.[31] Hull J, Ackerman H, Isles K, et al. Unusual haplotypic structure of IL-8, a susceptibility locus for a common respiratory virus[J]. Am J Hum Genet, 2001,69(2):413-419.[32] Taguchi A, Ohmiya N, Shirai K, et al. Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan[J]. Cancer Epidemiol Biomarkers Prev, 2005,14(11 Pt 1):2487-2493. |